Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk , nearly doubled annual income and investment ...

At a fundraising event, Bucks co-owner Wes Edens spoke on fighting obesity in Milwaukee, his playoff outlook, NBA expansion ...

Cross-sectional studies and Mendelian randomization show that insulin resistance and chronic inflammation mediate the ...

Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

We know that kids of color have worse outcomes in school in America. And kids in low income areas. And kids who don’t speak ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

Mounjaro, a GLP-1 receptor agonist, works by slowing digestion and suppressing appetite, leading to reduced caloric intake ...

Federal lawmakers are considering bills to reintroduce whole and 2% milk in school meals, a move that could reverse a ...

Federal lawmakers have revived bills that would allow whole and 2% milk to be served again in schools, in addition to the ...

Questions about insurance coverage for weight-loss drugs are getting more intense as cheaper alternatives go off the market.

Children with obesity and subclinical hypothyroidism have twice the risk for kidney damage compared with those without subclinical hypothyroidism, a retrospective study shows.